SCHEMBL10262172

SCHEMBL10262172

CO/N=C(\COc1ccc(COc2ccc(/C(CC(=O)OC)=N\OC)cc2)cc1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.67
SMN1; SMN2 Q16637 6/20 0.50
ALDH1A1 P00352 4/20 0.50
HTT P42858 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
RAB9A P51151 4/20 0.48
MAPT P10636 3/20 0.48
PLA2G4B P0C869 2/20 0.48
GAA P10253 1/20 0.48
MAOB P27338 1/20 0.48
NPC1 O15118 3/20 0.47
POLB P06746 1/20 0.47
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
PPARG P37231 1/20 0.46
PARP10 Q53GL7 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435065 0.93 FFAR1 (0.64) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL435066 0.93 FFAR1 (0.64) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL15239251 0.92 FFAR1 (0.71) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL10258712 0.92 FFAR1 (0.71) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL434771 0.89 FFAR1 (0.64) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL15239468 0.89 FFAR1 (0.64) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL434770 0.89 FFAR1 (0.64) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL10267704 0.88 FFAR1 (0.76) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL15239401 0.88 FFAR1 (0.76) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1
SCHEMBL10259016 0.87 FFAR1 (0.65) FFAR1SMN1; SMN2ALDH1A1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 FFAR1 24/4885SMN1; SMN2 2796/4885ALDH1A1 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.